The good correlation of IL-6 level and poor clinical outcome of lung cancer, breast cancer and pancreatic cancer patients indicates that IL-6 might be a pivotal molecule to overcome inflammation-correlated lung cancer metastasis [12–13]. Here, IL6 is linked to breast carcinoma.